Astellas’ Cresemba Review: Orphan Population With Unmet Need Vs. Limited Efficacy Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will vote on whether efficacy and safety evidence support approval of Astellas’ antifungal isavuconazonium for two indications, one of which has no controlled data.
You may also be interested in...
FDA Aspergillosis Biomarker Qualification Highlights New Drug Development Tool Process
FDA’s new drug development qualification process offers a pathway for outside groups to gain acceptance of specific biomarkers for regulatory purposes. FDA recently used the process to qualify a specific biomarker for a severe fungal infection.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.